Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cystic Fibrosis: early-phase trial registry
49 of 170 indexed Cystic Fibrosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #64 of 28,707 conditions by registered trial count.
170 US clinical trials · 49 currently recruiting · #64 of 28,707 conditions by registered trial count
Cystic Fibrosis: 170 US clinical trials tracked, 49 recruiting.
Cystic Fibrosis is the subject of 170 registered US clinical trials on ClinicalTrials.gov, 49 of them currently open to new participants. 34 are in Phase 3-4 (later-stage) and 61 in Phase 1-2 (earlier-stage). The most active sponsor is Vertex Pharmaceuticals Incorporated, running 20 of these trials.
Enrollment posture brief
Registry condition cystic-fibrosis
OPEN 49 | RECR 29% | LATE 34 | EARLY 61 | RANK #64 | SPON 20
Volume-matched condition peers
Nearest open-share peer: Prostatic Neoplasms (29% recruiting · 66 trials)
Cystic Fibrosis lists 49 open slots (29% of 170 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cystic Fibrosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cystic Fibrosis is recruiting below its size-band peers.
49 of 170 indexed trials (28.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cystic Fibrosis trials is spread across many organizations.
Vertex Pharmaceuticals Incorporated accounts for 20 of 170 trials (11.8%). 84 distinct sponsors appear on at least one study for this condition label.
-
Most Cystic Fibrosis trials plan to enrol fewer than 100 people.
Median target enrolment is 59 among the 170 trials that report a genuine target (sentinel values excluded). 107 of those (62.9%) plan for fewer than 100 participants.
-
Cystic Fibrosis research is mostly interventional.
121 interventional and 49 observational studies make up this index (71.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
170 total, page 1 of 4
Role of Genetic Factors in the Development of Lung Disease
National Heart, Lung, and Blood Institute (NHLBI)
NCT00001532
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
xCures
NCT06539169
Natural History of Bronchiectasis
National Heart, Lung, and Blood Institute (NHLBI)
NCT00943514
Acoustic Waveform Respiratory Evaluation
Indiana University
NCT06512064
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
Chris Goss
NCT05548283
Genetics of Insulin and Incretins in Cystic Fibrosis
Children's Hospital of Philadelphia
NCT01852448
Rare CFTR Mutation Cell Collection Protocol (RARE)
George Solomon
NCT03161808
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
University of Washington, the Collaborative Health Studies Coordinating Center
NCT06654752
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
Nicole Hamblett
NCT06504589
Natural History of Noncirrhotic Portal Hypertension
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT02417740
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
Mario Castro, MD, MPH
NCT04624490
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
NCT06154447
Exercise in Child Health
University of California, Irvine
NCT05359991
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
Vertex Pharmaceuticals Incorporated
NCT05422222
Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children
Sonya Heltshe
NCT04509050
Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)
Boston Children's Hospital
NCT06683092
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
ReCode Therapeutics
NCT06237335
Impact of Sinus Surgery on Individuals With Cystic Fibrosis
University of California, Los Angeles
NCT04469439
Remote Sputum Collection in Cystic Fibrosis
University of Pennsylvania
NCT06950892
Health Outcomes of Parents With Cystic Fibrosis-Aim 2
University of Pittsburgh
NCT06296394
Lung Transplant READY CF 2: CARING CF Ancillary RCT
University of Washington
NCT06032273
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
Vertex Pharmaceuticals Incorporated
NCT07283770
Markers of Osteoporosis in Cystic Fibrosis
University of Texas Southwestern Medical Center
NCT03921060
Regional Phenotyping of CF and Non-CF Bronchiectasis
Children's Hospital Medical Center, Cincinnati
NCT04793867
Role of Body Fat Distribution in Metabolic and Pulmonary Decline in Cystic Fibrosis (ORBIT-CF)
Emory University
NCT04002882
Sinus Disease in Young Children With Cystic Fibrosis
University of California, Los Angeles
NCT06191640
Estrogen Supplementation and Bone Health in Women With CF
Johns Hopkins University
NCT05704036
Hormonal Responses to a Mixed Meal in People With Cystic Fibrosis
University of Cincinnati
NCT06163482
FEED-Cystic Fibrosis (FEED-CF)
Emory University
NCT05766774
Regional Monitoring of CF Lung Disease
Children's Hospital Medical Center, Cincinnati
NCT06339593
Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials
Children's Hospital Medical Center, Cincinnati
NCT04580368
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
University of Pennsylvania
NCT01851694
BEGIN Novel ImagiNG Biomarkers
Children's Hospital Medical Center, Cincinnati
NCT05517655
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
University of Kansas Medical Center
NCT06364176
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
Emory University
NCT06350149
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
Vertex Pharmaceuticals Incorporated
NCT05668741
Skeletal Health and Bone Marrow Composition in Adolescents With Cystic Fibrosis
Massachusetts General Hospital
NCT06216704
Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome
Dartmouth-Hitchcock Medical Center
NCT05982795
Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF)
Milton S. Hershey Medical Center
NCT05998629
Continuous Glucose Monitoring and OGTT Screen for Cystic Fibrosis Related Diabetes in Cystic Fibrosis
Medical College of Wisconsin
NCT06560463
Quantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic Fibrosis
University of North Carolina, Chapel Hill
NCT06057714
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
University of Pennsylvania
NCT04731272
Assessing Tenapanor as a Treatment of CF-related Constipation.
Massachusetts General Hospital
NCT06810167
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis
SpliSense
NCT06429176
Personalized Theratyping Trial
George Solomon
NCT03587961
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
Spirovant Sciences
NCT06526923
The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes
Rhode Island Hospital
NCT05723445
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
Krystal Biotech
NCT05504837
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
Arcturus Therapeutics
NCT06747858
CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes
Nicole Hamblett
NCT03350828
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 34 |
| Phase 2 | 27 |
| Phase 3 | 19 |
| Phase 4 | 15 |
Top Sponsors
Named interventions
Most-linked intervention names on Cystic Fibrosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cystic Fibrosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cystic Fibrosis page
170 registered trials, 49 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 49 Cystic Fibrosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Vertex Pharmaceuticals Incorporated sponsors the most Cystic Fibrosis trials on record, review their full trial history before evaluating a specific study. See Vertex Pharmaceuticals Incorporated's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cystic Fibrosis condition card totals 170 registered trials; most-linked intervention Placebo; top US site state Colorado. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.